All In Biotech

Drug Trial Radar · NCT05076682

Reverse Triple Negative Immune Resistant Breast Cancer

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jun 30, 2022

Primary completion

Dec 31, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label, nine-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline, mifepristone) with immune checkpoint inhibitor or immune checkpoint inhibitor rechallenge(AK131) in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.

Conditions

  • Triple-negative Breast Cancer

Interventions

  • CholineDrug

    Choline 300mg tid or 500mg bid, p.o

  • anti-PD-1 antibody and chemotherapyDrug

    PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)

  • Sodium CromoglicateDrug

    Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)

  • EfavirenzDrug

    Efavirenz 600mg qd, p.o

  • SHR-A1811Drug

    4.8mg/kg q3w

  • SHR-A2102Drug

    6mg/kg q3w

  • SHR-1316Drug

    1200mg q3w

  • MecapegfilgrastimDrug

    Mecapegfilgrastim, 6mg, d3, q3w, s.c.

  • AK131Drug

    AK131, 40mg/kg i.v., q2w

  • TheophyllineDrug

    Theophylline, 100mg bid, p.o.

  • MifepristoneDrug

    Mifepristone, 200mg, qd, d1-3, qw, p.o.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months
  2. Immune changes in peripheral bloodTime frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.